Tyr694

Site Information
LAKAVDGyVKPQIKQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 447767

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 3 , 4 , 5 , 6 , 7 , 8 ) , phospho-antibody ( 1 , 9 , 10 , 12 , 13 , 14 ) , western blotting ( 1 , 13 , 14 )
Disease tissue studied:	liver cancer ( 13 )
Relevant cell line - cell type - tissue:	'brain, amygdala' ( 1 ) , 'brain, hippocampus' ( 1 ) , 'brain, hypothalamus' ( 1 ) , brain ( 4 , 5 , 6 , 7 , 8 ) , COS (fibroblast) ( 14 ) , GH4C1 (pituitary cell) ( 12 ) , granulosa ( 14 ) , H4IIe (hepatic) ( 13 ) , HIT-T15 (pancreatic) ( 10 ) , liver ( 3 ) , lung ( 3 ) , RAEC (endothelial) ( 9 ) , RIN (epithelial) ( 10 )

Upstream Regulation
Regulatory protein:	prolactin (human) ( 1 )
Putative in vivo kinases:	JAK2 (rat) ( 14 )
Treatments:	AG490 ( 14 ) , GH ( 10 , 11 ) , IL-22 ( 13 ) , leptin ( 10 ) , oxysterol ( 9 ) , PRL ( 14 )

References
1	Morales T, Lorenson M, Walker AM, Ramos E (2014) Both prolactin (PRL) and a molecular mimic of phosphorylated PRL, S179D-PRL, protect the hippocampus of female rats against excitotoxicity. Neuroscience 258, 211-7 24252319 Curated Info
2	Sandoval-Usme MC, et al. (2014) Simvastatin impairs growth hormone-activated signal transducer and activator of transcription (STAT) signaling pathway in UMR-106 osteosarcoma cells. PLoS One 9, e87769 24489959 Curated Info
3	Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876 22673903 Curated Info
4	Hu Y (2009) CST Curation Set: 8441; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
5	Tucker M (2009) CST Curation Set: 7151; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
6	Tucker M (2009) CST Curation Set: 7140; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
7	Tucker M (2009) CST Curation Set: 7146; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
8	Tucker M (2009) CST Curation Set: 7143; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
9	Romeo GR, Kazlauskas A (2008) Oxysterol and diabetes activate STAT3 and control endothelial expression of profilin-1 via OSBP1. J Biol Chem 283, 9595-605 18230613 Curated Info
10	Hekerman P, et al. (2005) Pleiotropy of leptin receptor signalling is defined by distinct roles of the intracellular tyrosines. FEBS J 272, 109-19 15634336 Curated Info
11	Hong-Brown LQ, et al. (2003) Sepsis-induced muscle growth hormone resistance occurs independently of STAT5 phosphorylation. Am J Physiol Endocrinol Metab 285, E63-72 12644450 Curated Info
12	Liu G, Robillard L, Banihashemi B, Albert PR (2002) Growth hormone-induced diacylglycerol and ceramide formation via Galpha i3 and Gbeta gamma in GH4 pituitary cells. Potentiation by dopamine-D2 receptor activation. J Biol Chem 277, 48427-33 12376552 Curated Info
13	Lejeune D, et al. (2002) Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 277, 33676-82 12087100 Curated Info
14	Frasor J, et al. (2001) PRL-induced ERalpha gene expression is mediated by Janus kinase 2 (Jak2) while signal transducer and activator of transcription 5b (Stat5b) phosphorylation involves Jak2 and a second tyrosine kinase. Mol Endocrinol 15, 1941-52 11682625 Curated Info